Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gli2 ASO
- Development stage
- Preclinical
- Lead developer
- Ionis Pharmaceuticals
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravesical, Intravenous
01
Overview
Gli2 ASO is an antisense oligonucleotide (ASO) designed to specifically target and down-regulate the expression of glioma-associated oncogene 2 (GLI2), a key transcription factor in the Sonic Hedgehog (SHH) signaling pathway. By binding to GLI2 mRNA, the ASO facilitates its degradation, leading to reduced GLI2 protein levels and the subsequent inhibition of SHH signaling, which is often aberrantly activated in various cancers. Preclinical studies have demonstrated that Gli2 ASO treatment can inhibit tumor cell proliferation, induce apoptosis, and enhance chemosensitivity to agents like paclitaxel in models of bladder cancer, castrate-resistant prostate cancer, and hepatocellular carcinoma.
- Other names
- GLI2 antisense oligonucleotideGLI-2 antisense oligonucleotideGLI 2 antisense oligonucleotideGLI2 ASOGLI-2 ASOGLI 2 ASO
02
Targets
GLI2
Beyond the preview
Go deeper on Gli2 ASO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gli2 ASO.